SCHEMBL5409269

SCHEMBL5409269

CC=CC(=O)NC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409266 1.00
SCHEMBL4591815 0.88 ALDH1A1 (0.35)
SCHEMBL10407848 0.82 ALDH1A1 (0.33)
SCHEMBL10407850 0.82 ALDH1A1 (0.33)
Acrylic Acid Methyl Ester SCHEMBL28834654 0.81 HCAR2 (0.39)
SCHEMBL13497222 0.80
SCHEMBL10536655 0.80
SCHEMBL19390594 0.78 ALDH1A1 (0.32)
SCHEMBL203011 0.78
SCHEMBL13886584 0.78 ALDH1A1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3168213-B1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2018-08-01 EP disclosed
CN-108026321-A For acrylic acid adhesive and the plasticizer of binder 道达尔销售服务公司 2018-05-11 CN disclosed
US-9753034-B2 Process for the identification of a compound which inhibits the binding of the first bromodomain of each of human BRD-2, BRD-3, and BRD-4 GLAXOSMITHKLINE LLC (US) 2017-09-05 US disclosed
EP-3168213-A1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS Glaxosmithkline LLC (US) 2017-05-17 EP disclosed
EP-2699551-B1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-11-16 EP disclosed
US-20160258946-A1 NOVEL PROCESS GLAXOSMITHKLINE LLC 2016-09-08 US disclosed
EP-2705032-B1 DIHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-06-15 EP disclosed
US-9360482-B2 Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 GLAXOSMITHKLINE LLC (US) 2016-06-07 US disclosed
US-9315487-B2 Tetrahydroquinoline derivatives useful as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2016-04-19 US disclosed
EP-2496558-B1 TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-03-30 EP disclosed
EP-2496945-A1 NOVEL PROCESS GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
EP-2496558-A1 THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
EP-2496557-A1 TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
EP-2496235-A1 BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
US-20120208798-A1 Tetrahydroquinoline Derivatives And Their Pharmaceutical Use GLAXOSMITHKLINE LLC 2012-08-16 US disclosed
US-20120208800-A1 Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases GLAXOSMITHKLINE LLC 2012-08-16 US disclosed
US-20120208814-A1 Thetrahydroquinolines Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-08-16 US disclosed
WO-2011054843-A1 BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed
US-7232923-B2 Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines IMPERIAL INNOVATIONS LIMITED (GB) 2007-06-19 US disclosed
US-20060183933-A1 Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines IMPERIAL COLLEGE INNOVATION LIMITED (GB) 2006-08-17 US disclosed